Premium
Induction of remission in hepatocellular carcinoma: A comparison of VP 16 with adriamycin
Author(s) -
Melia W. M.,
Johnson P. J.,
Williams Roger
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830115)51:2<206::aid-cncr2820510206>3.0.co;2-p
Subject(s) - medicine , hepatocellular carcinoma , gastroenterology , crossover study , complete response , carcinoma , drug , complete remission , randomized controlled trial , chemotherapy , surgery , oncology , pharmacology , pathology , placebo , alternative medicine
Following a pilot study of VP‐16.213 (180 mg/m 2 on 3 consecutive days at 2 weekly intervals) in the treatment of patients with hepatocellular carcinoma, the efficacy of the drug was compared with that of adriamycin in another 35 patients in a randomized crossover trial. Each drug gave a similar response rate (18 and 28%, respectively) but the duration of response was significantly longer in those receiving Adriamycin. Some patients who had not responded to treatment with Adriamycin had worthwhile remission with VP 16.